Get the Stockscreener App
22.46
2.00%
0.44
Celldex Therapeutics Inc stock is traded at $22.46, with a volume of 1.79M.
It is up +2.00% in the last 24 hours and up +0.45% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
See More
Previous Close:
$22.02
Open:
$22.11
24h Volume:
1.79M
Relative Volume:
1.65
Market Cap:
$1.49B
Revenue:
$5.79M
Net Income/Loss:
$-199.61M
P/E Ratio:
-7.4618
EPS:
-3.01
Net Cash Flow:
$-188.48M
1W Performance:
-11.92%
1M Performance:
+0.45%
6M Performance:
+0.00%
1Y Performance:
-36.34%
1-Day Range:
$21.56
$22.75
1-Week Range:
$20.37
$25.54
52-Week Range:
$14.40
$47.00
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Compare CLDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
22.46 | 1.63B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | Canaccord Genuity | Buy |
| Mar-20-25 | Initiated | Morgan Stanley | Overweight |
| Feb-13-25 | Initiated | UBS | Buy |
| Oct-07-24 | Initiated | Citigroup | Buy |
| Sep-30-24 | Initiated | Goldman | Neutral |
| Sep-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Dec-20-23 | Initiated | TD Cowen | Outperform |
| Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-22-23 | Initiated | Wells Fargo | Underweight |
| Sep-17-21 | Initiated | Jefferies | Buy |
| Sep-10-21 | Initiated | SVB Leerink | Outperform |
| Jul-22-21 | Initiated | Guggenheim | Buy |
| Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-07-16 | Initiated | Aegis Capital | Buy |
| Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
| Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-01-16 | Initiated | H.C. Wainwright | Buy |
| Aug-11-15 | Reiterated | Brean Capital | Buy |
| Aug-11-15 | Reiterated | Oppenheimer | Outperform |
| Aug-11-15 | Reiterated | ROTH Capital | Buy |
| Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
| Nov-17-14 | Reiterated | ROTH Capital | Buy |
| Mar-04-14 | Reiterated | Oppenheimer | Outperform |
| Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Feb-26-13 | Reiterated | Oppenheimer | Outperform |
| Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-02-12 | Reiterated | Oppenheimer | Outperform |
| Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
Lowering the mast: EoE theory down after Celldex phase II - BioWorld MedTech
The Strategic Reassessment of Celldex's Barzolvolimab Pipeline After EoE Setback: Identifying Resilience and Repurposing Potential in Biotech's Targeted Mast Cell Depletion Strategy - AInvest
Celldex stock price target lowered to $62 at Canaccord on EoE program halt - Investing.com Canada
Celldex Bullish On Barzolvolimab Despite Study Miss - insights.citeline.com
Why Is Celldex Therapeutics Stock Falling TodayCelldex Therapeutics (NASDAQ:CLDX) - Benzinga
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
NovaBay Names New CEO, Rocket Soars As FDA Lifts Clinical Hold, Celldex Plunges, Soligenix On Watch - RTTNews
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Celldex Therapeutics Plunges 16.74% on Drug Development Halt - AInvest
Celldex slides after Barzolvolimab hits target but fails to improve EoE symptoms in phase 2 trial - Seeking Alpha
LifeSci Capital Maintains a Buy on Celldex Therapeutics (CLDX), Keeps the PT - Yahoo Finance
What technical models suggest about Celldex Therapeutics Inc.’s comebackMarket Performance Report & Daily Entry Point Alerts - Newser
Celldex’s mast cell therapy fails to improve eosinophilic esophagitis By Investing.com - Investing.com Nigeria
Celldex’s mast cell therapy fails to improve eosinophilic esophagitis - Investing.com
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) - GlobeNewswire
Profound 71% Mast Cell Reduction: Celldex's Barzolvolimab EoE Trial Reveals Surprising Disconnect in Phase 2 - Stock Titan
Is Celldex Therapeutics Inc. stock bottoming outMarket Sentiment Report & Weekly Setup with High ROI Potential - Newser
Combining machine learning predictions for Celldex Therapeutics Inc.July 2025 Action & Risk Managed Trade Strategies - Newser
Can volume confirm reversal in Celldex Therapeutics Inc.2025 Top Decliners & Daily Growth Stock Investment Tips - Newser
How to build a dashboard for Celldex Therapeutics Inc. stockEarnings Miss & Real-Time Volume Trigger Notifications - Newser
Institutional scanner results for Celldex Therapeutics Inc.July 2025 Rallies & Real-Time Volume Analysis - Newser
Understanding Celldex Therapeutics Inc.’s price movement2025 Big Picture & Verified Entry Point Signals - Newser
Pattern recognition hints at Celldex Therapeutics Inc. upsideMarket Trend Review & Low Drawdown Trading Techniques - Newser
Analyzing recovery setups for Celldex Therapeutics Inc. investors2025 Short Interest & Real-Time Volume Trigger Notifications - Newser
Chart based analysis of Celldex Therapeutics Inc. trends2025 Growth vs Value & Fast Exit and Entry Strategy Plans - Newser
Live market analysis of Celldex Therapeutics Inc.Global Markets & Smart Money Movement Tracker - Newser
Momentum Screeners Rank Celldex Therapeutics Inc. in Top 5 TodayJuly 2025 Volume & Weekly High Return Opportunities - beatles.ru
Why Are Celldex Shares Tumbling After Hours? - Stocktwits
How Celldex Therapeutics Inc. stock performs during market volatilityJuly 2025 Reactions & Free Growth Oriented Trading Recommendations - Newser
Will Celldex Therapeutics Inc. continue its uptrend2025 Volatility Report & Daily Profit Maximizing Tips - Newser
Using R and stats models for Celldex Therapeutics Inc. forecastingMarket Performance Report & Free Long-Term Investment Growth Plans - Newser
Celldex Therapeutics Reports Increased R&D Expenses Amid Wider Losses - MSN
Can Celldex Therapeutics Inc. hit a new high this month2025 Support & Resistance & Long-Term Safe Return Strategies - Newser
Can trapped investors hope for a rebound in Celldex Therapeutics Inc.Market Weekly Review & Expert Curated Trade Ideas - Newser
Applying Wyckoff theory to Celldex Therapeutics Inc. stockQuarterly Risk Review & Accurate Entry and Exit Point Alerts - Newser
News impact scoring models applied to Celldex Therapeutics Inc.2025 Year in Review & Stock Timing and Entry Methods - Newser
Published on: 2025-08-16 21:03:31 - Newser
Top chart patterns to watch in Celldex Therapeutics Inc.Product Launch & Daily Entry Point Alerts - Newser
Trapped Investors in Celldex Therapeutics Inc. Await Breakout SignalTrade Analysis Summary & High Accuracy Swing Entry Alerts - beatles.ru
Real time pattern detection on Celldex Therapeutics Inc. stock2025 Growth vs Value & AI Enhanced Trading Signals - Newser
Building trade automation scripts for Celldex Therapeutics Inc.Market Movers & Risk Controlled Stock Alerts - Newser
Celldex Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Intraday Action & AI Enhanced Market Trend Forecasts - Newser
Celldex Executive Cashes In on Stock Sale - TipRanks
What’s the RSI of Celldex Therapeutics Inc. stockIndex Update & Free Weekly Watchlist of Top Performers - thegnnews.com
Trend analysis for Celldex Therapeutics Inc. this weekJuly 2025 Closing Moves & Advanced Swing Trade Entry Alerts - Newser
What to expect from Celldex Therapeutics Inc. in the next 30 daysQuarterly Market Review & Fast Gain Swing Alerts - Newser
What recovery options are there for Celldex Therapeutics Inc.Earnings Recap Report & Verified Chart Pattern Signals - Newser
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celldex Therapeutics Inc Stock (CLDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Marucci Anthony S | PRESIDENT & CEO |
Nov 11 '24 |
Buy |
26.82 |
11,500 |
308,430 |
40,284 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):